Adjuvant therapy for salivary gland carcinomas

Mutlay Sayan, Prashant Vempati, Brett Miles, Marita Teng, Eric Genden, Elizabeth G. Demicco, Krzysztof Misiukiewicz, Marshall Posner, Vishal Gupta, Richard L. Bakst

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Aim: We compared the clinical outcomes and toxicity profile among a retrospective cohort of patients with primary major salivary gland carcinomas (SGCs) treated with surgery followed by adjuvant radiation therapy (S+RT) versus surgery and adjuvant chemoradiotherapy (S+CRT). Patients and Methods: Twenty patients (71%) underwent S+RT and eight (29%) S+CRT at our Institution between 2006 and 2015. Microscopic positive margins were present in 54% of the patients. Results: The 3-year overall survival (OS) was 100% with S+RT and 87.5% with S+CRT (p=0.141) and locoregional control (LRC) was 95% with S+RT and 87.5% with S+CRT (p=0.383). There were no significant differences in the rate of acute (p=0.801) and late (p=0.714) toxicities. Conclusion: While we await randomized data, adjuvant CRT may be considered as a viable therapeutic option for patients at high-risk of local or regional recurrence, especially in those with a positive microscopic margin where further surgery may result in functional cranial neuropathies.

Original languageEnglish
Pages (from-to)4165-4170
Number of pages6
JournalAnticancer Research
Issue number8
StatePublished - Aug 2016


  • Adjuvant therapy
  • Chemoradiotherapy
  • Radiotherapy
  • Salivary gland carcinoma


Dive into the research topics of 'Adjuvant therapy for salivary gland carcinomas'. Together they form a unique fingerprint.

Cite this